DURHAM, N.C. (PRWEB) September 17, 2018
Registration is now open for the 2018 Chabner Colloquium: Answering the Big Questions in Cancer Research. This live CME event is sponsored by the Society for Translational Oncology (STO) in co-providership with Massachusetts General Hospital Cancer Center and in partnership with The Oncologist, STO's official journal. It will be held November 5, 2018, at The Liberty Hotel in Boston, Massachusetts.
Now in its ninth year, this one-day colloquium will highlight updates on the most promising targets for the development of new cancer treatments. Physician-scientists, industry professionals, and others interested in learning about advances in cancer biology leading to new approaches in clinical practice are invited to attend. Over 100 oncologists of all experience levels are in attendance each year. To view the agenda and confirmed faculty, please visit: https://sto-online.org/chabner-colloquia.
The meeting is named for Dr. Bruce A. Chabner, Allen Distinguished Investigator, Clinical Director, Emeritus at Massachusetts General Hospital Cancer Center, Professor of Medicine at Harvard Medical School, and Founding Editor-in-Chief of The Oncologist®. Dr. Chabner designs and leads this annual event. Dr. Chabner states, “It's a unique opportunity to share insights and perspectives between investigators and industry professionals working on novel therapeutic targets that will bring exciting changes in oncology practice in the years ahead."
The final session of the day will be the Junior Faculty Forum, in which the inaugural Young Investigator Award recipient will be announced. The award will be presented preceding the closing reception offering light hors d’oeuvres and a Marine Natural Life Sculptures art exhibit by Gar Waterman.
Society for Translational Oncology
STO is a 501(c)3 nonprofit professional organization dedicated to the continuing education of oncology professionals and to improvement in the quality and safety of care for cancer patients. The Society is committed to:
- Bringing knowledge and strategies for critical new developments in cancer treatment into the practice environment of the community oncologist;
- Bridging the “translational gap” between discovery and delivery of care to the patient; and
- Providing educational activities to improve physician competencies and strategies for screening, prevention, diagnosis, treatment, and management of patients with cancer.
About the Massachusetts General Hospital Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
U.S. News & World Report consistently ranks the Mass General Cancer Center as one of the top ten cancer centers in the country. Its nurses were the first in Massachusetts to achieve Magnet status from the American Nurses Credentialing Center in recognition of the hospital's exceptional nursing care.
Known for providing customized, innovative treatments and compassionate care to both adults and children, the Cancer Center comprises more than 37 treatment programs within 29 fully integrated, multidisciplinary disease centers and a vast array of support and educational services. Its network of affiliations extends throughout New England and the southeastern U.S.
The Cancer Center’s commitment to eradicating cancer is fueled by scientific investigation conducted as part of one of the largest hospital-based research programs in the nation. Through a powerful synergy between laboratory scientists and bedside physicians, the Mass General Cancer Center fosters innovation in all phases of cancer research. Physician investigators conduct nearly 400 clinical trials annually.
The Massachusetts General Hospital Cancer Center is proud to be a founding member of a Harvard Medical School consortium designated by the National Cancer Institute as a comprehensive cancer center. This prestigious seven-member center forms the largest cancer research collaboration in the country. The promising new treatments developed through this partnership are revolutionizing the future of cancer medicine.